01:52 , Feb 8, 2019 |  BC Week In Review  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
23:45 , Feb 7, 2019 |  BC Extra  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
22:53 , Jan 15, 2019 |  BC Week In Review  |  Clinical News

FDA approves Cabometyx for liver cancer

Exelixis Inc. (NASDAQ:EXEL) said Jan. 14 that FDA approved Cabometyx cabozantinib to treat hepatocellular carcinoma patients previously treated with Nexavar sorafenib. The approval comes two months after Exelixis’ partner Ipsen Group (Euronext:IPN; Pink:IPSEY) received approval...
00:30 , Jan 15, 2019 |  BC Extra  |  Company News

FDA approves Cabometyx for liver cancer

Exelixis Inc. (NASDAQ:EXEL) said Monday FDA approved Cabometyx cabozantinib to treat hepatocellular carcinoma patients previously treated with Nexavar sorafenib. The approval comes two months after Exelixis’ partner Ipsen Group (Euronext:IPN; Pink:IPSEY) received approval from the...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
23:15 , Dec 7, 2018 |  BioCentury  |  Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
20:35 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves Astellas’ Xospata in FLT3-positive AML

FDA approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation. The company said Xospata is the first...
21:56 , Nov 28, 2018 |  BC Extra  |  Company News

FDA approves Astellas’ Xospata in FLT3-positive AML

FDA approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation. The company plans to launch the drug,...
18:46 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Mirati reports updated confirmed ORR of 16% in Phase II of sitravatinib for NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus PD-1...